Arcus Biosciences, Inc.
RCUS US03969F1093
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 55% | -51% | -5% | -24% | -0% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Jarrett Jennifer COO |
15.05 USD |
37,792 Sold |
568,611 USD |
06/10/2025 | 08/10/2025 |
| Jarrett Jennifer COO |
14.54 USD |
12,500 Sold |
181,801 USD |
06/10/2025 | 06/10/2025 |
| Azoy Alexander DIR |
13.00 USD |
2,831 Sold |
36,803 USD |
29/09/2025 | 29/09/2025 |
| Azoy Alexander CCO |
11.88 USD |
1,579 Sold |
18,758 USD |
05/09/2025 | 05/09/2025 |
| Azoy Alexander CCO |
11.88 USD |
1,579 Sold |
18,758 USD |
05/09/2025 | 05/09/2025 |
| Rosen Terry J CEO |
10.18 USD |
19,800 Bought |
201,465 USD |
27/02/2025 | 27/02/2025 |
| Kaneko Yasunori |
10.06 USD |
20,000 Bought |
201,200 USD |
27/02/2025 | 27/02/2025 |
| Gilead Sciences, Inc. |
11.00 USD |
1,363,636 Bought |
14,999,996 USD |
18/02/2025 | 18/02/2025 |
| Goeltz Ii Robert C. CFO |
15.00 USD |
3,594 Sold |
53,910 USD |
31/12/2024 | 31/12/2024 |
| Azoy Alexander CCO |
15.17 USD |
3,007 Sold |
45,616 USD |
19/12/2024 | 19/12/2024 |